gefapixant (Pending FDA Approval)

Brand and Other Names:

Dosing & Uses

Chronic Cough

Pending FDA approval for chronic cough



Mechanism of Action

P2X3 receptor antagonist; purinergic receptor P2X3 is an ATP-gated ion channel found on sensory nerve fibers, predominantly C fibers, in the airway lining

Chemical stimuli, including adenosine triphosphate (ATP), can be released from airway lining cells due to processes including airway inflammation, irritation, and mechanical stress/injury; binding of extracellular ATP to P2X3 receptors on C fibers in the airway can be sensed as a signal of potential damage, creating an action potential, which may initiate coughing

Blockade of extracellular ATP binding to P2X3 receptors is thought to reduce sensory C fiber activation and subsequently, coughing



No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.